Novartis’ $1.7 billion Regulus Therapeutics buyout last month came after a hard-fought battle in which the Swiss pharma and ...

Rouzbeh Haghighat was serving on the board of Chinook Therapeutics at the time of the Novartis acquisition and, according to the DOJ’s allegations, used confidential information to conduct insider ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

Researchers found that nearly 28% of hospitalized chronic liver disease patients with acute kidney injury had alcohol-related disorders, as did almost 60% with hepatorenal syndrome.

Final draft guidance from NICE has backed NHS use of Filspari (sparsentan) for primary immunoglobulin A nephropathy (IgAN), ...

The U.S. FDA approved 20 drugs for market in April, slightly down from 22 in March, 16 in February and 12 in January. This ...

Atrasentan (Vanrafia) was approved in 2025 for the treatment of IgAN in people who are at risk of their disease getting worse quickly. It belongs to a class of medicines called endothelin receptor ...

Pluvicto, Vanrafia, and Fabhalta, all achieved approvals in their relevant indications. We had a global submission for remibrutinib and CSU and our OAV-101 IT gene therapy for patients with SMA ...

In early April, Novartis drug Vanrafia won accelerated FDA approval as a treatment for immunoglobulin A nephropathy (IgAN). That small molecule came from the $3.2 billion acquisition of Chinook ...

En concreto, Fabhalta, indicado para la anemia; y Vanrafia, aprobado para reducir los niveles elevados de proteínas en la orina en adultos con nefropatía primaria.